CONQUEST
4.4.2024 12:19:30 CEST | Business Wire | Press release
Conquest enters the Finnish renewable power market with the acquisition from BHM Renewables (a BHM group company) of a 182MW onshore wind portfolio developed by Winda Energy and the implementation of a broader strategic partnership towards further extensions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404783244/en/
Shutterstock, Wind Portfolio in Finland
Conquest, a fund manager focusing on the infrastructures of the energy transition in Europe, through its fund Conquest Infrastructure SLP – Sustainable 2, has completed the concomitant acquisitions of two wind farms developed by Winda Energy, the Finnish renewable energy developer majority-owned by Czech BHM Renewables, part of the investment firm BHM group. The two onshore wind projects have a combined capacity of 182MW. Furthermore, the cooperation encompasses additional onshore wind projects totalling 500MW.
The transaction allows Conquest to expand its renewable power platform and its footprint in the Nordics market, while maintaining a well-balanced and diversified approach towards investments targeted to the energy transition in Europe. The transaction represents an expected phased total investment of approximately 1 billion euros, to be gradually deployed between 2024 and 2028, offering a fully green investment in one of Europe’s most stable and robust economies.
The first two wind projects are at an advanced stage of development, with the first 182MW expected to reach ready-to-build by Q4 2024 and the rest expected to reach the same stage by Q4 2025. Winda Energy Oy will complete the development and manage the construction with expected start dates of commercial operations ranging from 2026 to 2028 for the portfolio.
Frederic Palanque, Founder and Managing Director of Conquest said: “Conquest is thrilled to enter, in partnership with Winda Energy, in sustainable real assets in a market recognized for its robust renewable energy fundamentals and its ambitious net zero roadmap.”
“We are happy to cooperate with Conquest, a dynamic and reliable partner on our growth journey. The transaction secures the completion of some of our flagship projects over the next years, enabling us to extend our contribution to Finland’s green energy transition.”, says Tuomas Hooli, CEO of Winda Energy.
Michal Prause, Associate Partner at BHM Renewables, said: “We are extremely pleased with the outcome of the transaction, reflecting the deep development skills, which our affiliate Winda has been demonstrating on the Finnish renewable power market over the years. We are looking forward to the strategic partnership with the highly professional asset management and investment teams of Conquest.”
ABOUT
Conquest
Established in 2012, Conquest is an alternative asset management firm invested in sustainable and long-term value stemming from European infrastructures. Conquest invests in and operates long-life, high- quality assets and businesses on behalf of its clients, which range from large institutional investors to single-family offices. With a team of 20 collaborators, based in Dublin and Paris, the firm manages assets worth circa 500 million euros and 25 investments across Europe.
BHM group
BHM group is a rapidly expending European investment firm that manages dozens of European companies in Europe. In the energy sector, BHM group is focused on investments in renewable energy sources, with an emphasis on wind and solar energy, and is active in six countries in Central Europe and Scandinavia. Due to its extensive experience and many successful projects, BHM group companies can provide comprehensive services, encompassing development, construction, and operation. BHM group focuses on long-term and stable partnerships that take into account healthy economic growth and are in line with internationally recognized standards of social responsibility and sustainability.
Winda Energy
Winda Energy Oy is a leading Finnish renewable energy project developer with its current development portfolio consisting of 3 GW of onshore wind and 1 GW of solar PV across Finland. Winda Energy has extensive experience in the renewable sector and takes projects from their initial design to the end of construction, most recently completing the construction of 200 MW of onshore wind in 2023. Winda Energy is majority owned by BHM group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404783244/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom